Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-α 2b treatment

被引：33

作者：

Ascierto, Paolo A. ^{[1
,2
]}

Napolitano, Maria ^{[1
,2
]}

Celentano, Egidio ^{[1
,2
]}

Simeone, Ester ^{[1
,2
]}

Gentilcore, Giusy ^{[1
,2
]}

Daponte, Antonio ^{[1
,2
]}

Capone, Mariaelena ^{[1
,2
]}

Caraco, Corrado ^{[1
,2
]}

Calemma, Rosa ^{[1
,2
]}

Beneduce, Gerardo ^{[1
,2
]}

Cerrone, Margherita ^{[1
,2
]}

De Rosa, Vincenzo ^{[1
,2
]}

Palmieri, Giuseppe ^{[3
]}

Castello, Giuseppe ^{[1
,2
]}

Kirkwood, John M. ^{[4
]}

Marincola, Francesco M. ^{[5
]}

Mozzillo, Nicola ^{[1
,2
]}

机构：

[1] Natl Tumor Inst, Unit Med Oncol & Innovat Therapy, Naples, Italy

[2] Natl Tumor Inst, Melanoma Cooperat Grp, Naples, Italy

[3] Inst Biomol Chem CNR, Sassari, Italy

[4] Univ Pittsburgh, Dept Med, Div Hematol Oncol, Inst Canc, Pittsburgh, PA USA

[5] NIH, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA

来源：

JOURNAL OF TRANSLATIONAL MEDICINE | 2010年 / 8卷

关键词：

HIGH-RISK MELANOMA; COOPERATIVE-ONCOLOGY-GROUP; ADJUVANT THERAPY; METASTATIC MELANOMA; LYMPH-NODES; ALPHA; TRIAL; AUTOIMMUNITY; FOXP3;

D O I：

10.1186/1479-5876-8-76

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Background: High-dose interferon-alpha 2b (IFN-alpha 2b) is the only approved systemic therapy in the United States for the adjuvant treatment of melanoma. The study objective was to explore the immunomodulatory mechanism of action for IFN-alpha 2b by measuring serum regulatory T cell (Treg), serum transforming growth factor-beta (TGF-beta), interleukin (IL)-10, and autoantibody levels in patients with melanoma treated with the induction phase of the high-dose IFN-alpha 2b regimen. Methods: Patients with melanoma received IFN-alpha 2b administered intravenously (20 MU/m(2) each day from day 1 to day 5 for 4 consecutive weeks). Serum Treg levels were measured as whole lymphocytes in CD4(+) cells using flow cytometry while TGF-beta, IL-10, and autoantibody levels were measured using enzyme-linked immunosorbent assays. Results: Twenty-two patients with melanoma received IFN-alpha 2b treatment and were evaluated for Treg levels. Before treatment, Treg levels were significantly higher in patients with melanoma when compared with data from 20 healthy subjects (P = 0.001; Mann-Whitney test). Although a trend for reduction of Treg levels following IFN-alpha 2b treatment was observed (average decrease 0.29% per week), statistical significance was not achieved. Subgroup analyses indicated higher baseline Treg levels for stage III versus IV disease (P = 0.082), early recurrence versus no recurrence (P = 0.017), deceased versus surviving patients (P = 0.021), and preoperative neoadjuvant versus postoperative adjuvant treatment groups (not significant). No significant effects were observed on the levels of TGF-beta, IL-10, and autoantibodies in patients with melanoma treated with IFN-alpha 2b. Conclusions: Patients with melanoma in this study showed increased basal levels of Treg that may be relevant to their disease and its progression. Treg levels shifted in patients with melanoma treated with IFN-alpha 2b, although no firm conclusions regarding the role of Tregs as a marker of treatment response or outcome can be made at present.

引用

页数：13